A year ago, Caribou Biotherapeutics’ CEO was telling Fierce Biotech that the company’s natural killer (NK) cell therapy program was the “tip of the spear” for its solid tumor strategy and didn’t hint at any plans to pause this work to conserve cash.

Actuate Therapeutics has set out plans for a modest $52 million IPO as the biotech seeks to fund a pair of trials for its glycogen synthase kinase‐3 beta (GSK-3β) drug.

As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel.

Sotio has struck a deal to fuse bispecifics with its antibody-drug conjugate (ADC) capabilities, agreeing to pay Biocytogen up to $325.5 million in upfront and milestone fees for rights to targeting molecules.

Vertex struck gold with the licensing of CRISPR Therapeutics’ sickle cell gene editing therapy in 2017. With that med now approved as Casgevy, Vertex is looking to extend its claim in gene editing therapy through a small licensing deal with South Korea’s Orum.

On the heels of early-stage data for monoclonal antibody visugromab showing “impressive and lasting responses” among patients with difficult to treat cancers, CatalYm has secured a $150 million series D.

Know Labs has put forward additional proof-of-concept data from its needle-free blood sugar monitor, designed to continuously scan the blood through a person’s skin.

Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release formulation of oral med danuglipron will be advanced into dose optimization studies.

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a $749,999 contract to Cambridge, Massachusetts-based Tiba Biotech to develop a new RNAi-based therapeutics, starting with a treatment for swine flu.

BD is seeing a shortage of its blood culture vials used to support a wide array of infectious disease diagnostics, and the FDA is urging healthcare providers to ration their current supplies and preserve them for patients at the highest risk.